[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100485296":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":10,"locations":24,"responsibleParty":37,"collaborators":10,"id":40,"slug":41,"hasResults":42,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":10,"eligibilityCriteria":45,"healthyVolunteers":42,"sex":46,"minAge":47,"maxAge":10,"enrollmentInfo":48,"targetDuration":10,"studyType":51,"phases":10,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":60,"whyStopped":10,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":69,"locationsCount":70},{"fullName":5,"class":6},"CHC Montlegia","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"CF patients before (3 days) and during (14 days) ETI treatment",null,"Patients over 12 years old and eligible will start ETI treatment ( current standart treatment).\n\n* Morning: Elexacaftor 100 mg, Tezacaftor 50 mg, Ivacaftor 75 mg, 2 tablets\n* Evening: Ivacaftor 150 mg",[13],"Drug: Elexacaftor 100 MG \u002F Ivacaftor 75 MG \u002F Tezacaftor 50 MG, 2 tablets each morning + Ivacaftor 150 mg one tablet each evening",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DRUG","Elexacaftor 100 MG \u002F Ivacaftor 75 MG \u002F Tezacaftor 50 MG, 2 tablets each morning + Ivacaftor 150 mg one tablet each evening","Patients will daily perform home spirometry and complete a respiratory symptoms score before (3 days) and during (first 14 days) ETI treatment.",[9],[21],{"name":22,"affiliation":5,"role":23},"Patrick Lebecque, PhD","PRINCIPAL_INVESTIGATOR",[25],{"facility":26,"status":10,"city":27,"state":10,"zip":28,"country":29,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":10},"Lebecque","Liège","4000","Belgium","BE",{"type":32,"coordinates":33},"Point",[34,35],5.56749,50.63373,{"lat":35,"lon":34},{"type":23,"investigatorFullName":38,"investigatorTitle":39,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Lebecque Patrick","Principal investigator, Clinical Professor","100485296","daily-monitoring-of-respiratory-symptoms-and-spirometry-during-eti-treatment-in-persons-with-cystic-fibrosis-100485296",false,"NCT05599230","Daily Monitoring of Respiratory Symptoms and Spirometry During ETI Treatment in Persons With Cystic Fibrosis.","Inclusion Criteria:\n\n* Cystic fibrosis diagnosis\n* At least 12 years old\n* Carrier of at least one copy of F508del mutation\n* Ability to perform reliable and reproducible spirometry\n* Medical and psychological stability\n* written consent\n* owning a smartphone\n\nExclusion Criteria:\n\n* Lung transplant\n* FEV1 \\> 120 % pr (%GLI) at the inclusion test\n* Pulmonary exacerbation","ALL","12 Years",{"count":49,"type":50},20,"ACTUAL","OBSERVATIONAL","The goal of this observational study is to provide optimal monitoring and support when initiating ETI treatment in eligible persons with cystic fibrosis (aged 12 y +) and to document on a daily basis, from 72 hours before the start of treatment and then for 14 days i) i) FEV1 changes (home spirometry), ii) ii) respiratory symptoms changes, iii) any possible side effects. Through a dedicated electronic platform, these data will be monitored every day by the medical team, which will be fully available for any questions or concerns patients may have.",[54],"Cystic Fibrosis",[56,57,58,59],"elexacaftor","time course","FEV1","Respiratory symptoms","UNKNOWN","2022-10-25",{"date":63,"type":50},"2022-10-31",{"date":65,"type":50},"2022-09-01",{"date":67,"type":68},"2022-11-30","ESTIMATED",{"name":5,"class":6},1]